

Daxxify® (daxibotulinumtoxinA-lanm)

When requesting Daxxify® (daxibotulinumtoxinA-lanm), the individual requiring treatment must be diagnosed with the following FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-Approved Indication

Daxxify is indicated for the treatment of cervical dystonia in adult patients.

Coverage Guidelines

Cervical Dystonia (Spasmodic Torticollis)

Individual must meet the following criterion for approval:

- Is at least 18 years of age.

Approval duration: 12 months

Dosing Recommendation

The recommended dose is 125 Units to 250 Units given intramuscularly as a divided dose among affected muscles. Daxxify should be administered no more frequently than every three months.

References

1. Daxxify® injection [prescribing information]. Newark, CA: Revance; January 2024.